NCT07376161Enrolling by invitation
Inflammation and Oxidative Stress in COPD
The Effect of Pulmonary Rehabilitation on Inflammation and Oxidative Stress in COPD
Source: ClinicalTrials.gov · Last updated 25 Feb 2026
Brief summary (registry, in English)
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, characterized by persistent airflow limitation, chronic inflammation, and increased oxidative stress. Despite optimal pharmacological treatment, many patients continue to experience symptoms, reduced exercise capacity, and frequent exacerbations. Pulmonary rehabilitation (PR) is an evidence-based, non-pharmacological intervention that improves symptoms, functional capacity, quality of life, and survival in patients with COPD; however, its biological effects on inflammatory and oxidative stress pathways remain insufficiently defined. This study aims to evaluate the effects of pulmonary rehabilitation on systemic inflammation and oxidative stress in patients with stable COPD. Serum levels of pro-inflammatory cytokines (interleukin-6 \[IL-6\], tumor necrosis factor alpha \[TNF-α\]) and the epithelial alarmin interleukin-33 (IL-33), which is released in response to airway epithelial injury, as well as nuclear factor erythroid 2-related factor 2 (NRF-2) gene and/or protein expression as a key regulator of antioxidant defense, will be measured before and after a standardized pulmonary rehabilitation program. By assessing changes in these biomarkers, this study seeks to determine whether pulmonary rehabilitation exerts disease-modifying effects beyond symptomatic improvement and functional outcomes. The findings are expected to provide novel insights into the biological mechanisms of pulmonary rehabilitation and to support its role as a targeted, cost-effective intervention in the comprehensive management of COPD.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 27 (estimated)
- First submitted
- 21 Jan 2026
- Start date
- 6 Jan 2026
- Primary completion date
- 1 May 2026
- Lead sponsor
- Esra Yazar
- Diseases
- COPD
- NCT number
- NCT07376161
What you commit to
- Study type: Observational
- Planned participants: 27
- From 6 Jan 2026 to the primary completion date, 1 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of acute COPD exacerbation or respiratory infection within the past 6 weeks
- Presence of other chronic lung diseases (e.g., bronchiectasis, interstitial lung disease, asthma)
- Active malignancy
- Severe or uncontrolled cardiovascular disease, including recent acute myocardial infarction or malignant arrhythmias
- Neurological, orthopedic, or psychiatric conditions that preclude objective functional assessment or participation in exercise training
Other
- Current smokers
- Use of antioxidant or vitamin supplementation within the past 4 weeks
- Determination by a cardiologist that participation in an exercise-based rehabilitation program is not medically appropriate
Who the study is looking for
- Adults aged 40-80 years with a diagnosis of stable COPD
- Airflow limitation defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (forced expiratory volume in 1 second / forced vital capacity \[FEV₁/FVC\] \< 70% and forced expiratory volume in 1 second \[FEV₁\] \< 70% predicted)
- Former smokers with a smoking history of at least 10 pack-years
- Clinically stable disease at the time of enrollment
- Ability and willingness to participate in the pulmonary rehabilitation program
- Provision of written informed consent
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istanbul Medeniyet University Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.